证券代码：301211 证券简称：亨迪药业 公告编号：2025-027 湖北亨迪药业股份有限公司 关于首次公开发行前已发行股份 上市流通提示性公告 本公司及董事会全体成员保证公告内容真实、准确、完整， 不存在任何虚假记载、误导性陈述或者重大遗漏。 特别提示： 限售的股东数量为 8 户，解除限售股份的数量为 216,000,000 股，占公司总股本 的 75.00%。 票上市之日起 36 个月，因公司股票上市后 6 个月内连续 20 个交易日的收盘价均 低于发行价 25.80 元/股，触发其股份锁定期延长承诺的履行条件，故本次申请解 除限售的 8 名股东限售期为自公司股票上市之日起 42 个月。上市流通日期为 2025 年 6 月 23 日(因 2025 年 6 月 22 日为非交易日，故顺延至下一交易日)。 一、首次公开发行前已发行股份概况 （一）首次公开发行股份情况 经中国证券监督管理委员会证监许可20213639 号文核准，亨迪药业向社会 公开发行人民币普通股（A 股）6,000.00 万股，于 2021 年 12 月 22 日在深圳证券 交易所上市交易。公司首次公开发行股票后，总股本由 18,000 万 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2025-027 湖北亨迪药业股份有限公司 关于首次公开发行前已发行股份 上市流通提示性公告 本公司及董事会全体成员保证公告内容真实、准确、完整， 不存在任何虚假记载、误导性陈述或者重大遗漏。 特别提示： 1、本次上市流通的限售股为公司首次公开发行前已发行的股份。本次申请解除 限售的股东数量为 8 户，解除限售股份的数量为 216,000,000 股，占公司总股本 的 75.00%。 2、本次解除限售股份限售起始日期为 2021 年 12 月 22 日，限售期限为自公司股 票上市之日起 36 个月，因公司股票上市后 6 个月内连续 20 个交易日的收盘价均 低于发行价 25.80 元/股，触发其股份锁定期延长承诺的履行条件，故本次申请解 除限售的8名股东限售期为自公司股票上市之日起42个月。上市流通日期为2025 年 6 月 23 日(因 2025 年 6 月 22 日为非交易日，故顺延至下一交易日)。 一、首次公开发行前已发行股份概况 （一）首次公开发行股份情况 经中国证券监督管理委员会证监许可[2021]3639 号文核准，亨迪药业向社会 公开发行人民 ...

国泰海通证券股份有限公司 一、首次公开发行前已发行股份概况 （一）首次公开发行股份情况 经中国证券监督管理委员会证监许可[2021]3639 号文核准，亨迪药业向社会 公开发行人民币普通股（A 股）6,000.00 万股，于 2021 年 12 月 22 日在深圳证券 交易所上市交易。公司首次公开发行股票后，总股本由 18,000 万股变更为 24,000 万股。其中无限售条件流通股为 54,767,687 股，占发行后总股本的比例为 22.82%， 有限售条件流通股为 185,232,313 股，占发行后总股本的比例为 77.18%。 （二）公司上市后股本变动情况 本次上市流通的限售股属于公司首次公开发行前已发行的股份，自公司首次 公开发行股票限售股形成至今，公司股本数量变化情况如下： 2023 年 5 月 19 日公司召开 2022 年年度股东大会，审议通过《2022 年度利润 分配及资本公积金转增股本预案》，同意以总股本 240,000,000 股为基数，以资本 公积向全体股东每 10 股转增 2 股，合计转增 48,000,000 股，本次分配后总股本 288,000,000 股。 除上述事项外，本次 ...

Group 1: Financial Performance - In 2024, the company's revenue was CNY 445,864,331.31, a decrease of 32.75% compared to the previous year [2][3] - The net profit attributable to shareholders was CNY 91,547,379.78, down 48.02% year-on-year [2][3] Group 2: Research and Development - In 2024, the company invested CNY 32,937,088.26 in R&D and reported one Chinese invention patent [2] - The company has obtained several drug registration certificates, including for ibuprofen sustained-release capsules and tolvaptan injection [3] Group 3: Future Plans - The company aims to reduce production costs and enhance market competitiveness through technological upgrades [3] - A new R&D center in Wuhan has been established to accelerate the development of a CDMO one-stop service platform [3] Group 4: Shareholder Engagement - The company currently has no plans for share buybacks but will disclose any future plans in accordance with regulations [2] - The company actively engages with investors through online platforms for Q&A sessions [2]

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

Core Viewpoint - Hendi Pharmaceutical has received the drug registration certificate for Ibuprofen Suspension from the National Medical Products Administration [1] Company Summary - Hendi Pharmaceutical (301211.SZ) announced the approval of the drug registration certificate for Ibuprofen Suspension [1]

证券代码：301211 证券简称：亨迪药业 公告编号：2025-025 湖北亨迪药业股份有限公司关于 布洛芬混悬液获得药品注册证书的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 湖北亨迪药业股份有限公司于近日收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的《药品注册证书》，现将相关情况公告如下： 公司已开展产品上市销售的前期准备工作，同时受产品的非唯一性、同类产 品竞争以及未来公司业务的推广效果、销售规模等因素影响，未来能否产生较大 收入具有不确定性。产品注册证书的取得在短期内对公司经营业绩不构成重大影 响。敬请广大投资者谨慎决策，注意防范投资风险。 特此公告。 二、药品的其他相关情况 布洛芬混悬剂，主要成分为布洛芬，属于非甾体抗炎药。其核心作用退热、 止痛、抗炎，药物微粒均匀分散在液体中，是儿童退烧止痛的常用且有效的药物， 对于吞咽片剂或胶囊困难的人（如术后、老人或有吞咽障碍者）也可使用。 布洛芬混悬剂注册分类为化学药品 4 类，按照与参比制剂质量和疗效一致的 技术要求审评并获批，批准后视同通过仿制药质量和疗效一致性评价。 三、对公司的 ...

一、药品基本情况 | 药品名称 | 托拉塞米注射液 | | --- | --- | | 剂型 | 注射剂 | | 规格 | 2ml：10mg；4ml：20mg； | | 注册分类 | 化学药品 3 类 | | 药品有效期 | 18 个月 | | 上市许可持有人 | 湖北亨迪药业股份有限公司 | | 生产企业 | 四川宏明博思药业有限公司 | | 受理号 | CYHS2303068；CYHS2303067 | | 证书编号 | 2025S01558；2025S01557 | | 药品批准文号 | 国药准字 H20254323；国药准字 H20254322 | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，经审 查，本品符合药品注册的有关要求，批准注册，发给药品注 | | | 册证书。质量标准、说明书、标签及生产工艺照所附执行。 | | | 药品生产企业应当符合药品生产质量管理规范要求方可生 | | | 产销售。 | 证券代码：301211 证券简称：亨迪药业 公告编号：2025-024 湖北亨迪药业股份有限公司关于 托拉塞米注射液获得药品注册证书的公告 本公司及董事会全体成员保证公告内容真实、准 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2025-023 湖北亨迪药业股份有限公司 关于参加湖北辖区上市公司 2025 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖北亨迪药业股份有限公司董事会 2025 年 6 月 5 日 为进一步加强与投资者的互动交流，湖北亨迪药业股份有限公司（以下简称"公 司"）将参加由湖北证监局、湖北省上市公司协会与深圳市全景网络有限公司联合举 办的"2025 年湖北辖区上市公司投资者集体接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP,参与本 次互动交流，活动时间为 2025 年 6 月 12 日（周四）14:00-16:40。届时公司高管将 在线就公司 2024 年度业绩、公司治理、发展战略、经营状况、融资计划、股权激励 和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃 参与！ 特此公告。 ...

Group 1 - The company has approved a profit distribution plan for the fiscal year 2024, which includes a cash dividend of RMB 2.50 per 10 shares, totaling RMB 72 million to be distributed to shareholders [1][2] - The total share capital used for the distribution is 288 million shares, and no bonus shares or capital reserves will be distributed this year [1][2] - The cash dividend will be subject to different tax treatments based on the type of shareholder, with specific rates for Hong Kong investors and domestic investors [2][3] Group 2 - The record date for the distribution is set for May 23, 2025, and the payment will be made on May 26, 2025 [3][4] - The distribution will be directly credited to the shareholders' accounts through their custodial securities companies [3] - The minimum selling price for shares held by certain stakeholders after the distribution will be adjusted to RMB 20.19 per share [4]